Therapeutic Bispecific Antibody Development Services
Therapeutic antibodies work by binding to and neutralizing extracellular target molecules. To overcome the limitations of therapeutic antibodies and to enhance their efficacy, bispecific antibodies (bsAb) that can engage two different targets simultaneously have been designed and developed. The physicochemical properties of bsAb are affected by combinations of different fragments. Alfa Cytology provides therapeutic bispecific antibody development services through screening, design, validation, and optimization.
Fig.1 Schematic representations of bispecific antibody (bsAb) formats. (Shim H., 2020)
Two Formats of bsAb
Many different bispecific antibodies have been developed. Although they have different molecular structures, practically all of them can be categorized into two main groups, fragment-based bsAb and Fc-based bsAb.
Fragment-based bsAb
Fragment-based bsAbs, consisting only of antibody variable domains, are the main class of bsAb formats. Because of their smaller size, they exhibit faster clearance and better tissue permeability in vivo, which significantly affects their pharmacological properties. These molecules are broadly similar in structure, consisting of two or more antibody fragments linked by flexible peptide junctions. Tandem scFv, dual affinity redirection proteins, and tandem double antibodies (TandAbs) have been more extensively studied in preclinical studies.
Fc-based bsAb
The fragment crystallizable (Fc) region plays a crucial role in antibody effector functions by binding to FcγRs and C1q. Additionally, it contributes to the extended half-life of immunoglobulins through pH-dependent binding to FcRn. Consequently, incorporating an Fc region in therapeutic antibodies is generally desirable, unless large size and longer half-life need to be avoided. Fc-based bsAbs can be classified into symmetric and asymmetric types, depending on their structural characteristics and binding specificities.
Our Services
Experience the power of therapeutic bispecific antibodies with Alfa Cytology's expert services. Our unrivaled expertise, cutting-edge technologies, and collaborative approach enable us to deliver innovative solutions for the next generation of targeted therapies.
Multiple Bispecific Antibody Format
Alfa Cytology specializes in diverse bispecific antibody formats. Our multidisciplinary approach ensures tailored strategies for successful development and accelerated translation of your bispecific antibody candidates.
- IgG-like bispecific antibodies
- Bispecific T-cell engagers molecules
- Tri-specific antibodies
- Dual-variable domain immunoglobulin
- Dual-affinity retargeting
- Single Domain Antibodies
One-stop Therapeutic Antibody Development
Alfa Cytology empowers scientists with extensive expertise in therapeutic bispecific antibody discovery and development by offering a comprehensive range of products, services, and support. Our one-stop solutions enable you to generate actionable data efficiently, with utmost confidence, and in a cost-effective manner.
Project Study
This phase involves conducting a comprehensive analysis and evaluation of the project's objectives, scope, feasibility, and requirements.
Bispecific Antibody Format Definition and Design
Alfa Cytology specializes in designing and producing a wide range of bispecific antibody formats for our clients. Our experienced team is well-equipped to create customized solutions that meet the specific needs and therapeutic goals of our clients.
Gene Synthesis
Our experienced team utilizes advanced technologies and high-quality synthesis platforms to meet the specific requirements of our clients.
Bispecific Antibody Production
Our experienced team employs advanced cell culture and purification methods to ensure efficient and reliable production of bispecific antibodies with the desired specificity and functionality.
Bispecific Antibody Characterization Service
Using advanced analytical techniques and assays, our experienced team evaluates critical parameters such as binding affinity, target engagement, stability, and functionality, ensuring the robust characterization of bispecific antibody candidates.
Our Advantages
Largest Toolbox
Strong Expertise
One-stop Solution
Short Turnaround
Unlock the potential of therapeutic bispecific antibodies with Alfa Cytology. Our comprehensive development services pave the way for groundbreaking advancements in targeted therapy, offering tailored solutions to accelerate the discovery and optimization of bispecific antibodies for enhanced outcomes. Please contact us for more information.
Reference
-
Shim H. (2020). Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules, 10(3), 360. https://doi.org/10.3390/biom10030360
For research use only.
Related Services
